Published in Lancet on November 09, 1996
Toxoid vaccine for pertussis. Lancet (1997) 2.43
Development of an improved vaccine for anthrax. J Clin Invest (2002) 1.95
Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants. Infect Immun (1999) 1.32
Diphtheria antitoxin levels in the Netherlands: a population-based study. Emerg Infect Dis (1999) 0.99
Pertussis vaccine: a critique. Pediatr Infect Dis J (2009) 0.91
Toward a new vaccine for pertussis. Proc Natl Acad Sci U S A (2014) 0.83
Oligosaccharide conjugates of Bordetella pertussis and bronchiseptica induce bactericidal antibodies, an addition to pertussis vaccine. Proc Natl Acad Sci U S A (2011) 0.78
Toxoid vaccine for pertussis. Lancet (1997) 0.75
Toxoid vaccine for pertussis. Lancet (1997) 0.75
Escherichia coli K1 capsular polysaccharide associated with neonatal meningitis. N Engl J Med (1974) 7.89
Epidemiology of Escherichia coli K1 in healthy and diseased newborns. Lancet (1975) 6.25
Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis (1983) 6.15
Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J Exp Med (1980) 5.32
A method for producing specific antisera with small doses of immunogen. J Clin Endocrinol Metab (1971) 4.38
Predominance of two newly described capsular polysaccharide types among clinical isolates of Staphylococcus aureus. Diagn Microbiol Infect Dis (1984) 4.10
The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med (2001) 4.08
Quantitative measurement of "natural" and immunization-induced Haemophilus influenzae type b capsular polysaccharide antibodies. Pediatr Res (1973) 3.89
Scandinavian model for eliminating measles, mumps, and rubella. Br Med J (Clin Res Ed) (1984) 3.25
Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection. J Infect Dis (1992) 2.98
Method for the serological typing of the capsular polysaccharides of Staphylococcus aureus. J Clin Microbiol (1985) 2.97
Lipid on capsular polysaccharides of gram-negative bacteria. J Biol Chem (1981) 2.91
Frequency of E. coli K antigens in urinary-tract infections in children. Lancet (1977) 2.89
Form variation in Escherichia coli K1: determined by O-acetylation of the capsular polysaccharide. J Exp Med (1979) 2.89
Bacterial antigens cross-reactive with the capsular polysaccharide of Haemophilus influenzae type b. Lancet (1971) 2.84
Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report. N Engl J Med (1987) 2.83
Use of antiserum agar for detection of Haemophilus influenzae type b in the pharynx. Pediatr Res (1975) 2.74
Relation between Escherichia coli K1 capsular polysaccharide antigen and clinical outcome in neonatal meningitis. Lancet (1974) 2.67
Vaccines for the prevention of encapsulated bacterial diseases: current status, problems and prospects for the future. Immunochemistry (1978) 2.65
Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet (1987) 2.59
The isolation and biologic activities of purified secretory IgA and IgG anti-Salmonella typhimurium "O" antibodies from rabbit intestinal fluid and colostrum. J Immunol (1971) 2.54
Enteric bacteria cross-reactive with Neisseria meningitidis groups A and C and Diplococcus pneumoniae types I and 3. Infect Immun (1972) 2.47
Serogroup identification of Neisseria meningitidis: comparison of an antiserum agar method with bacterial slide agglutination. J Clin Microbiol (1978) 2.44
Pathogenesis of neonatal Escherichia coli meningitis: induction of bacteremia and meningitis in infant rats fed E. coli K1. Infect Immun (1977) 2.39
Purification of antibodies with immunoadsorbents prepared using bromoacetyl cellulose. Immunochemistry (1967) 2.35
The epidemiology of typhoid fever in the Dong Thap Province, Mekong Delta region of Vietnam. Am J Trop Med Hyg (2000) 2.29
Invasive pneumococcal infections: incidence, predisposing factors, and prognosis. Rev Infect Dis (1985) 2.26
Differential complement resistance mediates virulence of Haemophilus influenzae type b. Infect Immun (1982) 2.23
Production of monovalent antisera by induction of immunological tolerance for capsular typing of Streptococcus pneumoniae. FEMS Microbiol Lett (1992) 2.19
Reexamination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella typhi. J Infect Dis (1984) 2.17
Induction of serum Haemophilus influenzae type B capsular antibodies in adult volunteers fed cross-reacting Escherichia coli 075:K100:H5. N Engl J Med (1975) 2.16
Gamma-A-immunoglobulin from rabbit colostrum. J Immunol (1966) 2.16
Clinical, bacteriological, and immunological characterisation of ampicillin-resistant Haemophilus influenzae type B. Lancet (1974) 2.14
A mAb recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival. Proc Natl Acad Sci U S A (1998) 2.13
Standardization and control of meningococcal vaccines, group A and group C polysaccharides. J Biol Stand (1977) 2.11
Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity. Infect Immun (1991) 2.11
Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates. Infect Immun (1983) 2.10
Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina. Infect Immun (1997) 2.05
Comparison of broad-range bacterial PCR and culture of cerebrospinal fluid for diagnosis of community-acquired bacterial meningitis. Clin Microbiol Infect (2007) 2.05
Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis. J Infect Dis (2000) 2.04
A review: relation between invasiveness and the K1 capsular polysaccharide of Escherichia coli. Pediatr Res (1976) 1.96
Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. Lancet (1997) 1.94
Haemophilus ducreyi, a cytotoxin-producing bacterium. Infect Immun (1992) 1.86
Cross-antigenicity and immunogenicity between capsular polysaccharides of group C Neisseria meningitidis and of Escherichia coli K92. J Infect Dis (1977) 1.84
Difference in structure between type b and nontypable Haemophilus influenzae populations. Infect Immun (1986) 1.84
Quantitative and qualitative analyses of serum antibodies elicited in adults by Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-tetanus toxoid conjugates. Infect Immun (1986) 1.79
A placebo-controlled trial of a pertussis-toxoid vaccine. N Engl J Med (1995) 1.78
Use of antiserum agar plates for serogrouping of meningococci. J Clin Pathol (1977) 1.74
Vaccination programme for eradication of measles, mumps, and rubella. Lancet (1982) 1.74
Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A. Infect Immun (1993) 1.70
Synthesis and immunologic properties in mice of vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides conjugated to Pseudomonas aeruginosa exotoxin A. Infect Immun (1990) 1.69
Evaluation of PCR for diagnosis of Bordetella pertussis and Bordetella parapertussis infections. J Clin Microbiol (1998) 1.68
Monoclonal antibodies against gastrointestinal tumour-associated antigens isolated as monosialogangliosides. Int Arch Allergy Appl Immunol (1983) 1.67
The Haemophilus ducreyi cytolethal distending toxin induces cell cycle arrest and apoptosis via the DNA damage checkpoint pathways. J Biol Chem (2000) 1.64
Comparative immunogenicity of group 6 pneumococcal type 6A(6) and type 6B(26) capsular polysaccharides. Infect Immun (1979) 1.61
Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine (1996) 1.59
Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals. J Exp Med (1987) 1.56
History of whooping cough in nonvaccinated Swedish children, related to serum antibodies to pertussis toxin and filamentous hemagglutinin. J Pediatr (1990) 1.53
Maturation indicators and the pubertal growth spurt. Am J Orthod (1982) 1.53
The cytolethal distending toxin from the chancroid bacterium Haemophilus ducreyi induces cell-cycle arrest in the G2 phase. J Clin Invest (1999) 1.52
Prospects for the prevention of bacterial meningitis with polysaccharide vaccines. Bull World Health Organ (1978) 1.52
Efficacy of Vi polysaccharide vaccine against strains of Salmonella typhi: reply. Vaccine (1998) 1.51
Parapertussis infection followed by pertussis infection. Lancet (1994) 1.49
Polyribitol-phosphate: an antigen of four gram-positive bacteria cross-reactive with the capsular polysaccharide of haemophilus influenzae type B. J Immunol (1974) 1.49
Bacillus pumilus polysaccharide cross-reactive with meningococcal group A polysaccharide. Infect Immun (1976) 1.49
Etiology of community-acquired pneumonia in children based on antibody responses to bacterial and viral antigens. Pediatr Infect Dis J (1989) 1.48
Protection against pneumococcal infection in mice conferred by phosphocholine-binding antibodies: specificity of the phosphocholine binding and relation to several types. Infect Immun (1983) 1.46
Protective levels of serum antibodies stimulated in infants by two injections of Haemophilus influenzae type b capsular polysaccharide-tetanus toxoid conjugate. J Pediatr (1989) 1.46
Synthesis, characterization, and some immunological properties of conjugates composed of the detoxified lipopolysaccharide of Vibrio cholerae O1 serotype Inaba bound to cholera toxin. Infect Immun (1992) 1.45
Preparation, characterization, and immunogenicity of conjugates composed of the O-specific polysaccharide of Shigella dysenteriae type 1 (Shiga's bacillus) bound to tetanus toxoid. Infect Immun (1991) 1.44
The infant rat as a model of bacterial meningitis. J Infect Dis (1977) 1.44
Height and height velocity in early, average and late maturers followed to the age of 25: a prospective longitudinal study of Swedish urban children from birth to adulthood. Ann Hum Biol (1991) 1.44
An outbreak of Hemophilus influenzae type b meningitis in an enclosed hospital population. J Pediatr (1976) 1.44
Age-related susceptibility to Haemophilus influenzae type b disease in rabbits. Infect Immun (1971) 1.43
Synthesis and immunological properties of conjugates composed of group B streptococcus type III capsular polysaccharide covalently bound to tetanus toxoid. Infect Immun (1990) 1.43
Comparative immunogenicities of Vi polysaccharide-protein conjugates composed of cholera toxin or its B subunit as a carrier bound to high- or lower-molecular-weight Vi. Infect Immun (1989) 1.42
Quantitative studies of the immunoglobulin sequence in the response of the rabbit to a somatic antigen. J Exp Med (1966) 1.40
Serum IgG antibody responses to pertussis toxin and filamentous hemagglutinin in nonvaccinated and vaccinated children and adults with pertussis. Clin Infect Dis (1999) 1.39
Relation between structure and immunologic properties of the Vi capsular polysaccharide. Infect Immun (1991) 1.39
Etiology of community-acquired pneumonia in patients requiring hospitalization. Eur J Clin Microbiol (1985) 1.39
Structural studies on the sialic acid polysaccharide antigen of Escherichia coli strain Bos-12. Biochemistry (1977) 1.38
Characterization of the Salmonella paratyphi C Vi polysaccharide. Infect Immun (1989) 1.37